• News

SGLT2 Inhibitors In The Treatment Of Type 2 Diabetes

  • Endocrinology Advisor
  • (February 08, 2018)

Barrie Weinstein, MD, assistant professor of medicine, endocrinology, diabetes and bone disease at the Icahn School of Medicine at Mount Sinai explains how she approaches risk-benefit discussions regarding sodium-glucose cotransporter2 (SGLT2) inhibitor use in patients who have type 2 diabetes. “Whenever I’m starting a patient on a new medication, I make sure to have an extensive discussion with the patient about the risk and benefits. SGLT2 inhibitors are an attractive option for patients with type 2 diabetes. In addition to lowering hemoglobin A1c and fasting plasma glucose, they have also been associated with weight loss, blood pressure lowering, and reduction in progression of albuminuria,” she said. She added that there has been a lot of positive noteworthy data about SGLT2 inhibitors; however, it is important to discuss the risks. “These medications can be very dehydrating, and is very important to talk to patients about staying hydrated with water throughout the day. If a patient becomes dehydrated while taking these medications, this potentially can lead to deleterious effects on the kidneys, although they can be reversible, or to the development of diabetic ketoacidosis.”

  • Barrie Weinstein, MD, Assistant Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai
    Learn more
Related Articles
Doctor adjusting microscope
Staten Island
Building exterior
Test tubes
Building exterior
award
nytgeneticsproject
research